Cargando…

Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination

Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is crit...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Perez, Maria, Montes-Casado, Maria, Conde, Patricia, Cervera, Isabel, Baranda, Jana, Berges-Buxeda, Marcos J., Perez-Olmeda, Mayte, Sanchez-Tarjuelo, Rodrigo, Utrero-Rico, Alberto, Lozano-Ojalvo, Daniel, Torre, Denis, Schwarz, Megan, Guccione, Ernesto, Camara, Carmen, Llópez-Carratalá, M Rosario, Gonzalez-Parra, Emilio, Portoles, Pilar, Ortiz, Alberto, Portoles, Jose, Ochando, Jordi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983822/
https://www.ncbi.nlm.nih.gov/pubmed/35401504
http://dx.doi.org/10.3389/fimmu.2022.845882
_version_ 1784682040920113152
author Gonzalez-Perez, Maria
Montes-Casado, Maria
Conde, Patricia
Cervera, Isabel
Baranda, Jana
Berges-Buxeda, Marcos J.
Perez-Olmeda, Mayte
Sanchez-Tarjuelo, Rodrigo
Utrero-Rico, Alberto
Lozano-Ojalvo, Daniel
Torre, Denis
Schwarz, Megan
Guccione, Ernesto
Camara, Carmen
Llópez-Carratalá, M Rosario
Gonzalez-Parra, Emilio
Portoles, Pilar
Ortiz, Alberto
Portoles, Jose
Ochando, Jordi
author_facet Gonzalez-Perez, Maria
Montes-Casado, Maria
Conde, Patricia
Cervera, Isabel
Baranda, Jana
Berges-Buxeda, Marcos J.
Perez-Olmeda, Mayte
Sanchez-Tarjuelo, Rodrigo
Utrero-Rico, Alberto
Lozano-Ojalvo, Daniel
Torre, Denis
Schwarz, Megan
Guccione, Ernesto
Camara, Carmen
Llópez-Carratalá, M Rosario
Gonzalez-Parra, Emilio
Portoles, Pilar
Ortiz, Alberto
Portoles, Jose
Ochando, Jordi
author_sort Gonzalez-Perez, Maria
collection PubMed
description Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population.
format Online
Article
Text
id pubmed-8983822
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89838222022-04-07 Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination Gonzalez-Perez, Maria Montes-Casado, Maria Conde, Patricia Cervera, Isabel Baranda, Jana Berges-Buxeda, Marcos J. Perez-Olmeda, Mayte Sanchez-Tarjuelo, Rodrigo Utrero-Rico, Alberto Lozano-Ojalvo, Daniel Torre, Denis Schwarz, Megan Guccione, Ernesto Camara, Carmen Llópez-Carratalá, M Rosario Gonzalez-Parra, Emilio Portoles, Pilar Ortiz, Alberto Portoles, Jose Ochando, Jordi Front Immunol Immunology Long-term hemodialysis (HD) patients are considered vulnerable and at high-risk of developing severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection due to their immunocompromised condition. Since COVID-19 associated mortality rates are higher in HD patients, vaccination is critical to protect them. The response towards vaccination against COVID-19 in HD patients is still uncertain and, in particular the cellular immune response is not fully understood. We monitored the humoral and cellular immune responses by analysis of the serological responses and Spike-specific cellular immunity in COVID-19-recovered and naïve HD patients in a longitudinal study shortly after vaccination to determine the protective effects of 1273-mRNA vaccination against SARS-CoV-2 in these high-risk patients. In naïve HD patients, the cellular immune response measured by IL-2 and IFN-ɣ secretion needed a second vaccine dose to significantly increase, with a similar pattern for the humoral response. In contrast, COVID-19 recovered HD patients developed a potent and rapid cellular and humoral immune response after the first vaccine dose. Interestingly, when comparing COVID-19 recovered healthy volunteers (HV), previously vaccinated with BNT162b2 vaccine to HD patients vaccinated with 1273-mRNA, these exhibited a more robust immune response that is maintained longitudinally. Our results indicate that HD patients develop strong cellular and humoral immune responses to 1273-mRNA vaccination and argue in favor of personalized immune monitoring studies in HD patients, especially if COVID-19 pre-exposed, to adapt COVID-19 vaccination protocols for this immunocompromised population. Frontiers Media S.A. 2022-03-23 /pmc/articles/PMC8983822/ /pubmed/35401504 http://dx.doi.org/10.3389/fimmu.2022.845882 Text en Copyright © 2022 Gonzalez-Perez, Montes-Casado, Conde, Cervera, Baranda, Berges-Buxeda, Perez-Olmeda, Sanchez-Tarjuelo, Utrero-Rico, Lozano-Ojalvo, Torre, Schwarz, Guccione, Camara, Llópez-Carratalá, Gonzalez-Parra, Portoles, Ortiz, Portoles and Ochando https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gonzalez-Perez, Maria
Montes-Casado, Maria
Conde, Patricia
Cervera, Isabel
Baranda, Jana
Berges-Buxeda, Marcos J.
Perez-Olmeda, Mayte
Sanchez-Tarjuelo, Rodrigo
Utrero-Rico, Alberto
Lozano-Ojalvo, Daniel
Torre, Denis
Schwarz, Megan
Guccione, Ernesto
Camara, Carmen
Llópez-Carratalá, M Rosario
Gonzalez-Parra, Emilio
Portoles, Pilar
Ortiz, Alberto
Portoles, Jose
Ochando, Jordi
Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_full Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_fullStr Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_full_unstemmed Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_short Development of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients After 1273-mRNA SARS-CoV-2 Vaccination
title_sort development of potent cellular and humoral immune responses in long-term hemodialysis patients after 1273-mrna sars-cov-2 vaccination
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8983822/
https://www.ncbi.nlm.nih.gov/pubmed/35401504
http://dx.doi.org/10.3389/fimmu.2022.845882
work_keys_str_mv AT gonzalezperezmaria developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT montescasadomaria developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT condepatricia developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT cerveraisabel developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT barandajana developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT bergesbuxedamarcosj developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT perezolmedamayte developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT sancheztarjuelorodrigo developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT utreroricoalberto developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT lozanoojalvodaniel developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT torredenis developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT schwarzmegan developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT guccioneernesto developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT camaracarmen developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT llopezcarratalamrosario developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT gonzalezparraemilio developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT portolespilar developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT ortizalberto developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT portolesjose developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination
AT ochandojordi developmentofpotentcellularandhumoralimmuneresponsesinlongtermhemodialysispatientsafter1273mrnasarscov2vaccination